Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| INCY | INCYTE CORP | 2026-02-18 03:22:25 | 101 | -0.16 | -0.16 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCY | 0000879169 | INCYTE CORP | US45337C1027 | 549300Z4WN6JVZ3T4680 | 943136539 | Nasdaq | 8731 | Services-Commercial Physical & Biological Research | 1231 | DE | 1801 AUGUSTINE CUT-OFF | WILMINGTON | DE | 19803 | UNITED STATES | US | 3024986700 | 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803 | 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803 | INCYTE INC | pharmaceuticals | 2002 | Bill Meury | 2,617 | http://incyte.com | 11,200,000,000 | 198,460,009 | 199,014,486 | Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. | 2026-02-12 15:45:57 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 11,200,000,000 | 1,300,000,000 | 13.1313 | 199,014,486 | 5,490,136 | 2.8369 |
| 2024 | 9,900,000,000 | -1,800,000,000 | -15.3846 | 193,524,350 | -31,001,778 | -13.8076 |
| 2023 | 11,700,000,000 | -2,500,000,000 | -17.6056 | 224,526,128 | 1,561,110 | 0.7002 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Barry P. Flannelly | Executive Vice President | 2020 | 480,542 | 0 | 2,342,694 | 308,057 | 45,034 | 4,116,884 |
| Steven H. Stein | Chief Medical Officer, Executive Vice President | 2020 | 576,321 | 0 | 1,418,393 | 369,457 | 22,022 | 3,326,750 |
| Hervé Hoppenot | Chief Executive Officer, President | 2020 | 1,094,731 | 0 | 8,317,223 | 1,403,468 | 47,746 | 16,378,192 |
| Christiana Stamoulis | Chief Financial Officer, Executive Vice President | 2020 | 585,468 | 0 | 1,743,359 | 375,321 | 28,604 | 4,154,250 |
| Vijay Iyengar | Executive Vice President | 2020 | 552,278 | 0 | 1,418,393 | 353,299 | 40,323 | 3,304,850 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 2,844 |
| 2024 | 2,617 |
| 2023 | 2,524 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 5,141,242,000 | 4,241,217,000 | 3,695,649,000 |
| Cost Of Revenue | 372,130,000 | 312,068,000 | 254,990,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 2,050,152,000 | 2,606,848,000 | 1,627,594,000 |
| General And Administrative Expenses | 1,376,206,000 | 1,242,157,000 | 1,161,293,000 |
| Operating Expenses | 3,626,383,000 | 4,179,851,000 | 3,075,124,000 |
| Operating Income | 1,514,859,000 | 61,366,000 | 620,525,000 |
| Net Income | 1,286,650,000 | 32,615,000 | 597,599,000 |
| Earnings Per Share Basic | 6.59 | 0.16 | 2.67 |
| Earnings Per Share Diluted | 6.41 | 0.15 | 2.65 |
| Weighted Average Shares Outstanding Basic | 195,204,000 | 207,110,000 | 223,628,000 |
| Weighted Average Shares Outstanding Diluted | 200,700,000 | 210,530,000 | 225,928,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 3,097,817,000 | 1,687,829,000 | 3,213,376,000 |
| Marketable Securities Current | — | — | 442,667,000 |
| Accounts Receivable | 1,024,407,000 | 853,154,000 | 743,557,000 |
| Inventories | 101,060,000 | 58,872,000 | 62,972,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 5,023,902,000 | 3,239,030,000 | 4,645,402,000 |
| Marketable Securities Non Current | — | — | 187,716,000 |
| Property Plant And Equipment | 730,885,000 | 763,411,000 | 751,513,000 |
| Other Assets Non Current | 18,166,000 | 10,848,000 | 52,107,000 |
| Total Assets Non Current | 1,934,071,000 | 2,205,292,000 | 2,136,705,000 |
| Total Assets | 6,957,973,000 | 5,444,322,000 | 6,782,107,000 |
| Accounts Payable | 209,938,000 | 197,465,000 | 109,601,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 90,723,000 | 58,865,000 | 73,325,000 |
| Total Liabilities Current | 1,515,170,000 | 1,641,847,000 | 1,240,379,000 |
| Long Term Debt | 0 | 0 | 0 |
| Other Liabilities Non Current | 165,270,000 | 167,543,000 | 149,151,000 |
| Total Liabilities Non Current | 275,325,000 | 354,847,000 | 351,891,000 |
| Total Liabilities | 1,790,495,000 | 1,996,694,000 | 1,592,270,000 |
| Common Stock | 198,000 | 193,000 | 224,000 |
| Retained Earnings | 213,769,000 | -1,072,881,000 | 160,385,000 |
| Accumulated Other Comprehensive Income | 25,462,000 | -13,121,000 | 13,106,000 |
| Total Shareholders Equity | 5,167,478,000 | 3,447,628,000 | 5,189,837,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 93,286,000 | 89,248,000 | 82,660,000 |
| Share Based Compensation Expense | 249,346,000 | 266,058,000 | 215,889,000 |
| Other Non Cash Income Expense | -14,857,000 | 9,053,000 | -22,579,000 |
| Change In Accounts Receivable | 170,772,000 | 111,586,000 | 98,678,000 |
| Change In Inventories | 58,513,000 | 127,633,000 | 170,151,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 6,562,000 | 88,159,000 | -167,945,000 |
| Change In Other Liabilities | -148,202,000 | 278,939,000 | 230,614,000 |
| Cash From Operating Activities | 1,413,498,000 | 335,337,000 | 496,487,000 |
| Purchases Of Marketable Securities | 295,507,000 | 258,370,000 | 456,020,000 |
| Sales Of Marketable Securities | 284,631,000 | 231,269,000 | 305,784,000 |
| Acquisition Of Property Plant And Equipment | — | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -102,610,000 | 157,517,000 | -207,677,000 |
| Tax Withholding For Share Based Compensation | 76,818,000 | 40,302,000 | 28,550,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 221,762,000 | 49,301,000 | 35,836,000 |
| Repurchase Of Common Stock | 0 | 2,023,975,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 101,039,000 | -2,021,547,000 | -20,033,000 |
| Change In Cash | 1,410,218,000 | -1,525,770,000 | 262,101,000 |
| Cash At End Of Period | 3,097,817,000 | 1,687,829,000 | 3,213,376,000 |
| Income Taxes Paid | 212,178,000 | 373,056,000 | 378,206,000 |
| Interest Paid | — | — | 2,551,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 6.59 | 0.16 | 2.67 |
| Price To Earnings Ratio | 14.9879 | 431.6875 | 23.5169 |
| Earnings Growth Rate | 4,018.75 | -94.0075 | 74.5098 |
| Price Earnings To Growth Ratio | 0.0037 | -4.5921 | 0.3156 |
| Book Value Per Share | 26.4722 | 16.6464 | 23.2075 |
| Price To Book Ratio | 3.7311 | 4.1493 | 2.7056 |
| Ebitda | 1,594,542,000 | 497,199,000 | 1,061,016,000 |
| Enterprise Value | 16,182,482,080 | 12,617,258,700 | 10,828,226,120 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0 | 0 | 0 |
| Capital Expenditures | 60,760,000 | 101,146,000 | 94,863,000 |
| Free Cash Flow | 1,352,738,000 | 234,191,000 | 401,624,000 |
| Return On Equity | 0.249 | 0.0095 | 0.1151 |
| One Year Beta | 0.5427 | 0.4583 | 0.4648 |
| Three Year Beta | 0.4979 | 0.5154 | 0.5818 |
| Five Year Beta | 0.5563 | 0.6133 | 0.6452 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Heeson Lee | EVP, Head of Incyte Intl | 2026-02-02 | 111 | D | 38,041 |
| Morrissey Michael James | EVP, Head of Tech. Operations | 2026-02-02 | 185 | D | 34,065 |
| Morrissey Michael James | EVP, Head of Tech. Operations | 2026-01-20 | 429 | D | 34,250 |
| Trotta Matteo | EVP, GM, Dermatology US | 2026-01-16 | 8,542 | A | 8,542 |
| Issa Mohamed Khairie | EVP, Head of US Oncology | 2026-01-16 | 14,237 | A | 14,237 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Shelley M Capito | Senator | 2018-12-08 | Sale (Full) | 2018-11-12 | Spouse | $1,001 - $15,000 |
| Shelley M Capito | Senator | 2017-10-06 | Purchase | 2017-09-08 | Spouse | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Rob Bresnahan | 2025-05-31 | PA08 | Sale | 2025-05-15 | — | $1,001 - $15,000 |
| Daniel Goldman | 2023-04-17 | NY10 | Sale | 2023-03-06 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Driehaus Capital Management LLC | 2025-12-31 | 12,680,488 | 128,384 | 98.77 |
| JANUS HENDERSON GROUP PLC | 2025-12-31 | 2,215,007 | 22,421 | 98.7916 |
| Cinctive Capital Management LP | 2025-12-31 | 2,345,491 | 23,747 | 98.77 |
| Woodline Partners LP | 2025-12-31 | 59,325,410 | 600,642 | 98.77 |
| Engineers Gate Manager LP | 2025-12-31 | 3,679,973 | 37,258 | 98.77 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| BAIRD FUNDS INC | 2025-12-31 | Institutional Class | CCGIX | 137,719 | 13,602,505.63 | 3.0042 |
| BAIRD FUNDS INC | 2025-12-31 | Investor Class | CCGSX | 137,719 | 13,602,505.63 | 3.0042 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXKWX | 25,121 | 2,481,201.21 | 0.0269 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXVIX | 25,121 | 2,481,201.21 | 0.0269 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXETX | 828 | 81,781.56 | 0.0112 |